Background: Pancreatic cancer outcomes in Nigeria are predominantly reported from public hospitals. This study describes clinical characteristics, treatment patterns, and survival outcomes at a private oncology center in Lagos.

Methods: A retrospective study of 42 patients diagnosed with pancreatic cancer and managed at Lakeshore Cancer Center (2014–2024) was conducted. Data were extracted from the institutional cancer registry. Overall survival was estimated using the Kaplan–Meier method.

Results: Most patients were female (57.1%) and aged 60 years or older (64.3%). Common presenting symptoms included abdominal pain (78.6%), weight loss (71.4%), and jaundice (64.3%). Among patients with comorbidities (n = 33), diabetes (57.6%) and hypertension (48.5%) were most frequent. Advanced disease predominated, with 76.2% presenting at Stage IV and only one patient (2.4%) at Stage I. Tumours were mainly located in the pancreatic head (64.3%). Treatment modalities were not mutually exclusive: chemotherapy was administered to 45.2% (n = 19), best supportive care to 35.7% (n = 15), and surgery to 11.9% (n = 5), while 21.4% (n = 9) had no documented treatment. No patient received radiotherapy. Median overall survival was 17 weeks (95% CI: 3.9–24.6), and mean survival was 21.2 weeks (95% CI: 14.0–28.3). Female patients had a longer median survival than male patients (23 versus 17 weeks).

Conclusion: Most patients presented with advanced disease and had poor survival, typically less than 5 months, consistent with reports from public hospitals. Access to private healthcare did not result in earlier diagnosis. Strengthening referral pathways, improving access to diagnostics, and expanding health insurance coverage may improve outcomes.